Terumo Neuro has today announced the launch of the Aneurysm Treatment Alliance at the 2025 European Society of Minimally Invasive Neurological Therapy (ESMINT) annual congress (3–5 September, Marseille, France).
The Aneurysm Treatment Alliance is a new Europe, the Middle East and Africa (EMEA) initiative created to strengthen engagement with physicians, streamline collaboration, and highlight Terumo Neuro’s differentiated haemorrhagic portfolio for aneurysm treatment, according to a press release from the company.
By providing standardised tools and a collaborative platform, the alliance is intended to support physicians in advancing patient care across the region, and will feature:
- Comprehensive portfolio access, including the WEB device, LVIS EVO stent, FRED X flow diverter, hydrogel coils and bare platinum coils
- Elevated collaboration and purposeful engagement with physicians that “extends beyond presentations”, emphasising shared expertise, cross-regional perspectives, and dialogue that drives clinical advancement
- Cross-regional learnings, enhancing the exchange of insights and best practices across the EMEA region to improve the quality and consistency of physician engagement
- Cross-collaboration opportunities, expanding awareness and education on integrated implantable device solutions for aneurysm therapy
“Our haemorrhagic portfolio leads the way in delivering innovative solutions, grounded in strong clinical outcomes, that empower physicians to confidently treat a wide range of aneurysms,” said Sebastien Chabeauti, vice president and general manager, EMEA, Terumo Neuro. “The Aneurysm Treatment Alliance brings this commitment to life by providing physicians across EMEA with practical tools and collaborative opportunities to elevate aneurysm treatment. This launch also reflects our laser-focused dedication to physician partnerships, innovation, and improving patient outcomes worldwide.”
